Table 2.
Description of Patient Clinical Characteristics at the Visit Date
| Characteristic |
All Patients N = 414 |
SU* + MF† n = 341 |
TZD** + MF† n = 73 |
| A1c at on the follow-up period (mean ± std) | 7.3 ± 1.2 | 7.4 ± 1.3 | 7.0 ± 1.2 |
| Patients at A1C Goal (%) | 24.88% | 23.75% | 30.14% |
| Therapy patients were using at the time of visit (also referred as "current therapy") – (%) | |||
| Monotherapy (%) | 3.16% | 3.24% | 2.78% |
| Combination Therapy | |||
| Metformin + Sulfonylurea (%) | 57.52% | 69.12% | 2.78% |
| Metformin + TZDs (%) | 16.26% | 3.24% | 77.78% |
| Sulfonylurea + TZD (%) | 0.24% | 0.29% | 0.00% |
| Sulfonylurea + Alpha glucosidase inhibitors (%) | 0.73% | 0.88% | 0.00% |
| Sulfonylureas + TZD + Metformin (%) | 11.89% | 12.65% | 8.33% |
| Sulfonylureas + Alpha glucosidase inhibitors + Metformin (%) | 5.83% | 7.06% | 0.00% |
| Metformin + TZD + Alpha glucosidase inhibitors (%) | 1.46% | 0.59% | 5.56% |
| Sulfonylureas + TZD + Metformin + Alpha glucosidase inhibitors (%) | 2.91% | 2.94% | 2.78% |
Note: These patients received SU or TZD after failing metformin at index date. Current therapy can be different than this combination, as patients may have received other therapies in addition to SU or TZD. For the purpose of this study, each patient was required to have a minimum of 1 year of time-period between the index date and the visit date. Patients receiving insulin during that period were excluded from this study.
* SU: Sulfonylurea
† MF: Metformin
** TZD: Thiazolidinedione